Clinical trial
Docetaxel in Treating Children With Recurrent Solid Tumors
NCT00002825 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00002825 |
|---|---|
| Title | Docetaxel in Treating Children With Recurrent Solid Tumors |
| Official title | A PHASE II STUDY OF DOCETAXEL (TAXOTERE) (NSC# 628503) IN CHILDREN WITH RECURRENT SOLID TUMORS |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors, Neuroblastoma, Sarcoma |
| Intervention type | Biological, Drug |
| Interventions | filgrastim, docetaxel |
| Enrollment | 20 |
| Start date | Jan 1, 1997 |
| Primary completion | Dec 1, 2004 |
| First posted | Mar 1, 2004 |
| Last update posted | Feb 5, 2013 |
| Countries | Australia, Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: